Inactivation of viruses using novel protein A wash buffers

Biotechnology Progress

Volumn 31, Issue 2, 2015, Pages 406-413

  Bolton, Glen R ^a   Selvitelli, Keith R ^a   Iliescu, Ionela ^a   Cecchini, Douglas J ^a  

^a BIOGEN   (United States)

Author keywords

Fc fusion; Mixed mode; Monoclonal antibody; Protein A; Purification; Viral clearance; Viral inactivation

Indexed keywords

AMINO ACIDS; ION EXCHANGE RESINS; MONOCLONAL ANTIBODIES; NITROGEN COMPOUNDS; POSITIVE IONS; PURIFICATION; SALT REMOVAL; SODIUM CHLORIDE; SULFUR COMPOUNDS; VIRUSES;

ANION EXCHANGE RESINS; CATION EXCHANGES; FC FUSION PROTEINS; HYDROPHOBIC INTERACTIONS; MIXED MODE; PROTEIN A; VIRAL CLEARANCE; VIRAL INACTIVATION;

HYDROPHOBICITY;

AMMONIUM SULFATE; ARGININE; DETERGENT; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; SODIUM CHLORIDE; STAPHYLOCOCCUS PROTEIN A;

AFFINITY CHROMATOGRAPHY; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; PH; PROCEDURES; VIRUS; VIRUS INACTIVATION;

AMMONIUM SULFATE; ANTIBODIES, MONOCLONAL; ARGININE; CHROMATOGRAPHY, AFFINITY; DETERGENTS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOGLOBULIN FC FRAGMENTS; MODELS, MOLECULAR; SODIUM CHLORIDE; STAPHYLOCOCCAL PROTEIN A; VIRUS INACTIVATION; VIRUSES;

EID: 84928214427     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.2024     Document Type: Article

References (20)

1. Yamane-Ohnuki N, Satoh M. Production of therapeutic antibodies with controlled fucosylation. mAbs 2009;1:230-236.
2. Pharmaceutical Manufacturers Association. Biotechnology medicines in development. Pharmaceutical Manufacturers Association, Washington, DC, April 2010.
3. Kelley B. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. mAbs 2009;1:443-452.
4. Shukla AA, Hinckley P. Host cell protein clearance during protein A chromatography: Development of an improved column wash step. Biotechnol Prog. 2008;24:1115-1121.
5. Miesegaes GR, Lute SC, Read EK, Brorson KA. Viral clearance by flow-through mode ion exchange columns and membrane adsorbers. Biotechnol Prog. 2014;30:124-131.
6. Miesegaes G, Lute S, Brorson K. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng. 2010;106:238-246.
7. Bywater R, Eriksson GB, Ottosson T. Desorption of immunoglobulins from Protein A-Sepharose CL-4B under mild conditions. J Immunol Methods 1983;64:1-6.
8. Curtis S, Lee K, Blank GS, Brorson K, Xu Y. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol Bioeng. 2003;84:179-186.
9. Ghose S, Nagrath D, Hubbard B, Brooks C, Cramer SM. Use and optimization of a dual-flowrate loading strategy to maximize throughput in protein-A affinity chromatography. Biotechnol Prog. 2004;20:830-840.
10. Mahajan E, George A, Wolk B. Improving affinity chromatography resin efficiency using semi-continuous chromatography. J Chromatogr A 2012;1227:154-162.
11. Pollock J, Bolton G, Coffman J, Ho SV, Bracewell DG, Farid SS. Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J Chromatogr A. 2013;1284:17-27.
12. Ransohoff TC, Bisschops MAT. Continuous processing methods for biological products. WO Patent 2012/078677 A2 (2013).
13. Roberts PL, Walker CP, Feldman PA. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography. Vox Sang. 1994;67:69-71.
14. Soice N, Hubbard J, Zhang Y, Hamzik J. Methods for purifying a target protien from one of more impurities in a sample. US Patent 2011/0065901 A1 (2011).
15. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-.ANG. resolution. Biochemistry 1981;20:2361-2370.
16. Grönberg A, Eriksson M, Ersoy M, Johansson HJ. A tool for increasing the lifetime of chromatography resins. mAbs 2011;3:192-202.
17. Kozloff LM, Lute M, Crosby LK, Wong R, Stern B. Critical arginine residue for maintaining the bacteriophage tail structure. J Virol. 1969;3:217-227.
18. Yamasaki H, Tsujimoto K, Koyama AH, Ejima D, Arakawa T. Arginine facilitates inactivation of enveloped viruses. J Pharm Sci. 2008;97:3067-3073.
19. McCue JT, Selvitelli K, Cecchini D, Brown R. Enveloped virus inactivation using neutral arginine solutions and applications in therapeutic protein purification processes. Biotechnol Prog. 2014;30:108-112.
20. Conley LE, Tao Y. Methods and compositions for inactivating enveloped viruses. WO Patent 2014/025771 A2 (2014).